中基長壽科學(00767.HK)與湖北國藥簽署商品供需合同
格隆匯4月7日丨中基長壽科學(00767.HK)發佈公吿,於2022年4月6日,公司全資附屬公司深圳市中基健康科學有限公司與國藥控股湖北國大藥房有限公司(湖北國藥)簽署商品供需合同。此次簽約標誌着雙方正式結為戰略合作伙伴,開啟了集團美國生物製品ZJ1VC緩釋片在國內取得合法經營銷售權後,在國內零售佈局的第一步。接下來集團將繼續加大與國內線下醫藥零售百強連續的開發合作,打造更惠民的線下實體管道。
湖北國藥是國藥集團在湖北設立的核心企業,旗下零售藥店近200家,其中武漢市直營門店50餘家,周邊地市100餘家,市內現有員工500餘人,業務規模在藥物零售行業中位居前列。
董事會相信基於此次戰略協定的達成,公司將憑藉湖北國藥全方位、強資源、立體化的行銷管道模式,建立集團佈局廣、覆蓋深的醫藥零售管道,進一步完善集團在長壽科學領域的佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.